How Ipamorelin Works in the Research

The gist

If you want to know what does ipamorelin peptide do at the level of biology, here is the short version. Ipamorelin is a tiny synthetic peptide that fits into a specific docking site on cells in the pituitary gland — the ghrelin receptor, the same one the hunger hormone uses. When ipamorelin docks, it tells those cells to release a quick burst of growth hormone.

The clever part is what it does not do. Older peptides that hit the same receptor also nudged the body to make cortisol (a stress hormone) and prolactin (a hormone tied to lactation). Ipamorelin was engineered to leave those mostly alone — it raises growth hormone cleanly. That selectivity is its whole reason for being. Because it triggers growth hormone through a different doorway than the body's own growth-hormone-releasing hormone, researchers often pair it with a partner peptide that uses the other doorway. Everything below explains each step with the studies that established it.

Step one: the receptor

Ipamorelin is a selective agonist of GHS-R1a — the growth hormone secretagogue receptor type 1a, better known as the ghrelin receptor. This is the receptor that the body's natural hunger hormone, ghrelin, activates, which is why ipamorelin is described as a ghrelin mimetic ^[1]. The receptor sits on somatotrophs, the pituitary cells that store growth hormone. The peptide's structure — a non-natural Aib residue at position one plus two D-form amino acids — is what lets it survive long enough in the body to reach and bind this receptor without being broken down ^[1].

Step two: the signal inside the cell

Once ipamorelin binds GHS-R1a, the receptor activates the Gq/PLC pathway — an internal signaling cascade that raises the concentration of calcium inside the somatotroph. That rise in intracellular calcium is the trigger that causes the cell to release its stored growth hormone as a discrete pulse ^[1]. This is a different internal route than the one GHRH analogs use, which work through the cAMP pathway — and that difference is precisely why the two classes combine well, each adding a separate push toward growth-hormone release.

Step three: the growth-hormone pulse and what follows

The output is a single, sharp growth-hormone pulse. In humans, that pulse peaks about 40 minutes after dosing and the peptide clears with a terminal half-life near 2 hours ^[2]. Downstream, growth hormone signals the liver to produce IGF-1 (insulin-like growth factor 1), the mediator of many growth-hormone effects — though in short rodent studies IGF-1 was not always elevated, indicating some effects are driven by the pulse itself rather than sustained IGF-1 ^[4]. Beyond the pituitary, the same receptor signaling has documented peripheral effects: direct insulin release from pancreatic islet cells ^[8] and prokinetic effects on gut motility.

What is ipamorelin peptide

To close the loop on what is ipamorelin peptide: it is a synthetic pentapeptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, derived from GHRP-1 by removing the central Ala-Trp dipeptide, and acting as the first highly selective growth hormone secretagogue ^[1]. "Selective" is the operative word — it releases growth hormone without the cortisol and prolactin rise that defined its predecessors ^[1]. It is wholly synthetic, not a natural human peptide, and has no approved medical use. The fuller study record is on the Ipamorelin research page, and the reported and cited effects are on Ipamorelin effects.